DP Technology nominates Lp-PLA2 inhibitor DPT0416 as a preclinical candidate for Alzheimer's treatment.

DP Technology, an "AI for Science" company, has announced the nomination of DPT0416, a CNS-penetrable Lp-PLA2 inhibitor, as a preclinical candidate for Alzheimer's disease treatment. Lp-PLA2 is a phospholipase linked to inflammation and neurovascular dysfunction, key factors in Alzheimer's development. This nomination highlights DP Technology's drug design platform, RiDYMO.